Drug Profile
HIV-1 vaccine - Sumagen
Alternative Names: Killed-whole HIV-1 vaccine; SAV-001; SAV-001HLatest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator University of Western Ontario
- Developer Sumagen
- Class AIDS vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes - HIV infections
Highest Development Phases
- No development reported HIV-1 infections
Most Recent Events
- 28 Jul 2018 No recent reports of development identified for phase-I development in HIV-1-infections in USA (IM, Injection)
- 03 Sep 2013 HIV-1 vaccine - Sumagen is available for licensing as of 03 Sep 2013. http://www.sumagen.co.kr/english/
- 03 Sep 2013 Immunogenicity & adverse events data from a phase I trial in HIV-1 infections released by Sumagen